Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) Director Wendy B. Young purchased 6,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was acquired at an average price of $10.21 per share, with a total value of $61,260.00. Following the completion of the acquisition, the director now directly owns 6,000 shares in the company, valued at $61,260. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.
Rapport Therapeutics Trading Up 4.9 %
Shares of RAPP opened at $10.51 on Friday. The stock has a fifty day moving average of $13.54 and a two-hundred day moving average of $18.74. Rapport Therapeutics has a fifty-two week low of $6.43 and a fifty-two week high of $29.74.
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of RAPP. TRV GP V LLC acquired a new position in Rapport Therapeutics in the 4th quarter valued at $126,579,000. TRV GP VI LLC acquired a new stake in shares of Rapport Therapeutics during the 4th quarter worth $17,194,000. FMR LLC increased its holdings in shares of Rapport Therapeutics by 10.1% during the 3rd quarter. FMR LLC now owns 5,486,468 shares of the company’s stock worth $112,363,000 after buying an additional 503,117 shares during the last quarter. Geode Capital Management LLC acquired a new stake in shares of Rapport Therapeutics during the 3rd quarter worth $4,133,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Rapport Therapeutics by 9.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,143,384 shares of the company’s stock worth $20,285,000 after buying an additional 95,976 shares during the last quarter.
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Featured Articles
- Five stocks we like better than Rapport Therapeutics
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- Growth Stocks: What They Are, What They Are Not
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Quiet Period Expirations Explained
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.